纯合突变CYP2C19等位基因致氯巴占消除缺陷的临床后果
报告一例63岁白人男性因自愿服用氯巴占1200 mg入ICU的病例,住院延长至46天。初始血浆氯巴占和N-去甲基氯巴占浓度分别为8.3和14.8 mg/L,第30天NCLB仍高达14.3 mg/L,提示消除障碍。基因检测发现CYP2C19*2纯合突变等位基因无酶活性。予苯巴比妥100 mg用10天诱导NCLB代谢后患者好转。作者指出NCLB为CLB主要活性代谢物,半衰期更长、稳态浓度更高,CYP2C19基因多态性可导致严重中毒。
要点
- 氯巴占过量后若NCLB持续高浓度(本例第30天仍14.3 mg/L),应想到CYP2C19纯合突变致消除缺陷。
- 本例CLB初始血浆浓度8.3 mg/L、NCLB 14.8 mg/L,NCLB半衰期40–50 h、CLB半衰期18 h。
- CYP2C19*2纯合无酶活性者,NCLB代谢受阻可致住院显著延长(本例46天)。
- 苯巴比妥100 mg用10天诱导NCLB代谢后患者好转,为个案经验。
- CLB与NCLB的NCLB/CLB比值受CYP2C19基因型影响,个体间差异大。
适用人群与场景
- 自愿服用氯巴占过量的患者,尤其出现NCLB消除延迟时。
- 本例为63岁白人男性,因自愿药物中毒收入重症监护室。
处置流程与药物剂量
- 本例予苯巴比妥100 mg用10天以诱导NCLB代谢,患者好转。
- 监测血浆CLB和NCLB浓度:本例初始分别为8.3和14.8 mg/L,第30天NCLB为14.3 mg/L。
- 基因检测发现CYP2C19*2纯合突变等位基因无酶活性。
红旗征与不能漏的情况
- NCLB高浓度持续不降(本例第30天14.3 mg/L)提示消除缺陷,需警惕住院延长。
研究设计与关键结果
- 病例报告:63岁白人男性自愿服用氯巴占1200 mg入ICU,住院46天。
- 初始血浆CLB 8.3 mg/L、NCLB 14.8 mg/L;第30天NCLB 14.3 mg/L。
- 基因检测示CYP2C19*2纯合突变无酶活性。
- 予苯巴比妥100 mg用10天诱导NCLB代谢后患者好转。
证据类型、等级与局限
- 证据类型:病例报告。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为CYP2C19多态性医师普遍不熟悉,可能导致严重中毒。
- 对氯巴占过量后NCLB持续高浓度者,可考虑检测CYP2C19基因型(作者讨论中提及基因型影响代谢)。
- 本例用苯巴比妥100 mg用10天诱导代谢后好转,属个案经验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Introduction: Voluntary drug intoxication with benzodiazepines is common and in most cases without consequences. We report an interesting case of voluntary drug intoxication with clobazam (CLB) in a patient with a homozygous mutated CYP2C19 genotype. Case report: A 63-year-old Caucasian man was admitted to an intensive care unit for voluntary drug intoxication with CLB (1200 mg) complicated by prolonged hospitalization (46 days). The levels of CLB and N-desmethylclobazam (NCLB) in plasma were initially 8.3 and 14.8 mg/L. The persistence of a high concentration of NCLB (14.3 mg/L on day 30) suggested a lack of elimination. A homozygous mutated allele of CYP2C19*2 without enzyme activity was discovered. To overcome this phenotype, NCLB metabolism was induced by administering 100 mg of phenobarbital for 10 days, allowing patient improvement. Discussion: NCLB is the major active metabolite of CLB with a longer half-life and much higher steady-state plasma concentrations compared to the parent drug. The half-life elimination of CLB is 18 h that of NCLB is between 40 and 50 h. However, there is considerable inter-individual variation in the metabolism of CLB and of the report NCLB/CLB under the dependence of genotype of CYP2C19. These polymorphisms are not generally well-known by physicians and may lead to severe poisoning.
参考来源
- Boels D, Chhun S, Meyer G, et al. Clinical consequences related to a defective elimination of clobazam caused by homozygous mutated CYP2C19 allele. Clin Toxicol (Phila). 2019. PMID: 30696292. doi:10.1080/15563650.2018.1550198
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。